Contract Notice Detail
Summary Information
Summary Information
Base Total Price:
5,139.60 Euro
Forbid offers above base price:
Request Reference:
CA-3369-AQ-E-240105-L
Request Name:
Aquisição de BEVAcizumab 25 mg/ml Sol inj Fr 4 ml IV BIOSSIMILAR (Alymsys/ZENTIVA) - CPA 491/2023
Phase:
Tendering Phase
State:
Awarded
Description:
Aquisição de BEVAcizumab 25 mg/ml Sol inj Fr 4 ml IV BIOSSIMILAR (Alymsys/ZENTIVA) - CPA 491/2023
Procedure Type:
VortalGOV - Acquisition under a Framework Agreement (via Direct Award)
Lot Name
Lot Base Price
Expected Duration
B325 - BEVACIZUMAB [25 MG/ML; 100 MG/ 4 ML; CONC P/A SOL P/A PERFUSÃO; FRS]
5,139.60 Euro
5
(
Days
)
Object of the Contract
Object of the Contract
Type of Contract:
Supplies Acquisition
Main Object CPV Main Category:
Estrada de Santa Luzia 4904-858 União das freguesias de Viana do Castelo (Santa Maria Maior e Monserrate) e Meadela Viana do Castelo PORTUGAL
CPV Main Vocabulary
33600000-6 - Pharmaceutical products
CPV Supplementary Vocabulary
Additional Classifications List
Scheduling
Scheduling
Request online publishing date:
1/16/2024 1:08 PM
(UTC 0 hours)
National official publishing date and time (DR):
9/4/2023 12:00 AM
(UTC +1 hour)
Due datetime for receiving replies:
1/19/2024 6:00 PM
(UTC 0 hours)
Financial Settings
Financial Settings
Define Advance Payments?
No
Define Warranties?
No
Contract Documents
Contract Documents
Document Name
Description
Doc Classification
Convite.pdf
Convite.pdf
Download
Anexo A.pdf
Anexo A.pdf
Download
Anexo A.xlsx
Anexo A.xlsx
Download
Object of contract
This contract is subject to renewal?
No
The procurement is related to a project and/or programme financed by European Union funds?
No
Legal, economic, financial and technical information
The contract is reserved to sheltered workshops and economic operators aiming at the social and professional integration of disabled or disadvantaged persons?
No
Questionnaire
Questionnaire
1
Questionário
1.1
Lote 1
Section for Lot - B325 - BEVACIZUMAB [25 MG/ML; 100 MG/ 4 ML; CONC P/A SOL P/A PERFUSÃO; FRS]
1.1.1
Lote 1
Bill of Quantities
*
(Os valores indicados não incluem o IVA)
Solicitou requisitos adicionais nesta lista de preços.
Preço Total
Total without VAT
0,00
EUR
Cód. Artigo
Referência Interna
Descrição
Qt
Unidade
Preço Unitário
Preço Total
Reference
B325
Internal Reference
Description
BEVACIZUMAB [25 MG/ML; 100 MG/ 4 ML; CONC P/A SOL P/A PERFUSÃO; FRS]
Qty
120,00
Unit
UN
Price per Unit
Total
Comentários do Comprador:
500162166 | Laboratórios Pfizer, Lda. | CPA:2023491/96/0495 | NºAIM:5772116; 500233810 | Roche - Farmacêutica Química, Lda. | CPA:2023491/150/0378 | NºAIM:5252382; 502942959 | Amgen Biofarmacêutica, Lda. | CPA:2023491/103/0258 | NºAIM:5789110; 504362674 | Ciclum Farma Unipessoal, Lda. | CPA:2023491/248/0443 | NºAIM:5813100; 507002571 | Pharmakern Portugal, Produtos Farmacêuticos Soc. Unipessoal, Lda. | CPA:2023491/379/0403 | NºAIM:5845029;
Evaluation
Evaluation
Evaluation General Settings
Evaluation General Settings
Evaluation guideline
LowestPrice
Evaluation Method
Manual
Evaluation Items
Evaluation Items
Name
Lot
Regras de avaliação para o lote 1
1 - B325 - BEVACIZUMAB [25 MG/ML; 100 MG/ 4 ML; CONC P/A SOL P/A PERFUSÃO; FRS]
Critérios de Adjudicação
Peso (%)**
1
Preço
100
Define tie breaking rules?
Yes
No
Public Messages
Public Messages
Type
Reference
Subject
Date
No items found...